Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Sodium-dependent serotonin transporter (SERT), encoded by the SLC6A4 gene, is a critical membrane protein that regulates the concentration of serotonin in the synaptic cleft by facilitating its reuptake into presynaptic neurons (UniProt P31645). Beyond its primary orthosteric binding site where most selective serotonin reuptake inhibitors (SSRIs) act, SERT possesses a distinct extracellular allosteric site located within the transporter's vestibule (Zhong et al., 2012, Nature). Binding of specific molecules, most notably the antidepressant escitalopram, to this allosteric site induces a conformational change that stabilizes the drug's binding at the orthosteric site, thereby slowing its dissociation and enhancing the inhibition of serotonin transport (Chen et al., 2005, Journal of Biological Chemistry). This allosteric mechanism is thought to contribute to the superior clinical efficacy and potency of certain SSRIs in treating major depressive disorder and various anxiety disorders (StatPearls, 'Selective Serotonin Reuptake Inhibitors'). Dysregulation of SERT-mediated transport is a hallmark of several psychiatric conditions, making the transporter a primary focus for pharmacological intervention. However, therapeutic modulation of SERT is associated with safety concerns such as serotonin syndrome, gastrointestinal issues, and sexual dysfunction (PubMed, PMC3181864). Ongoing research into the structural biology of the allosteric site aims to discover novel ligands that can more precisely tune serotonergic signaling with fewer side effects.
Allosteric modulation of the serotonin transporter (SERT) involves the binding of a ligand to a secondary site (the S-site) located in the extracellular vestibule, which induces a conformational change that stabilizes the binding of inhibitors at the primary orthosteric site (Zhong et al., 2012; Chen et al., 2005).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-dependent serotonin transporter (SERT) - extracellular allosteric site (SERT).